A 2015 phase I study published in the Journal of Clinical Oncology by Do et al. evaluated the Wee1 kinase inhibitor AZD1775 (MK-1775) as a single agent in patients with refractory solid tumors.

Authors

• Person: Not available Organization: Nature
  Perspectives on cancer therapy—synthetic lethal precision medicine ...

Sources

• Perspectives on cancer therapy—synthetic lethal precision medicine ... www.nature.com Nature via serper

Referenced by nodes (1)

• Adavosertib concept